Levofloxacin revealed as first effective treatment for multi-drug resistant TB

23 Nov 2023
www.pmlive.com
Clinical ResultQualified Infectious Disease ProductClinical Study
Two landmark clinical trials involving researchers at University College London (UCL) have demonstrated that levofloxacin is the first effective treatment to prevent multidrug-resistant tuberculosis (MDR-TB).
Results from both trials were announced at the Union WUniversity College London (UCL)in Paris, France.levofloxacinmultidrug-resistant tuberculosis (MDR-TB)
Annually, around 500,000 people develop tuberculosis (TB), an infectious disease caused by a type of bacteria that affects the lungs, that is resistant to multiple antibiotics.
Led by Stellenbosch University in South tuberculosis (TB)MRC Clinical Trials Unit (CTU) at UCL responsible for trial management and statistical analysis, the TB-CHAMP trial involved 922 children and adolescents exposed to an adult with MDR-TB in their household.
ResultsStellenbosch Universityin reduced the risk of MDR-TB disease by 56%, with very few sUCL effects reported.MDR-TB
Additionally, after levofloxacinly 1.1% of children dMDR-TB diseaseompared to 2.6% who received a placebo.
The second trial, VQUIN, led by the Woolcock Institute of Medical Research and the University of Sydney, involved 2,041 adults and children living with a person with MDR-TB across ten provinces in Vietnam and revealed that levofloxacin reduced the risk of MDR-TB by 45%.
Levofloxacin is an antibiotic medicaWoolcock Institute of Medical Research a numberUniversity of Sydneyions, including respiratory tract infections, pneumonia and abdMDR-TB infections.levofloxacinMDR-TB
Levofloxaciners further analysed the data from both trials and confirmed that levofloxabacterial infectionsective in prrespiratory tract infectionsndpneumonia.abdominal infections
UCLng standard methods as well as a novel Bayesian approach developed by Beckylevofloxacinprofessor Ian White from the MRC CTU at UCL, across both trials in total, levofloxacin reduced the risk of developing MDR-TB by 60%.
Trinh Duong, MRC CTU at UCL, TB-CHAMP trial statistician and lead for the combined analysis, said: “Combining data from two trial UCLulations using novel methodologlevofloxacinat UCL may pave the way for combMDR-TBfuture paediatric and adult trial data.”
The MDR-TB preventative UCLatment is due to be considered by an advisory committee of the World Health Organization in December 2023 to consider new recommendations for children aUCLadolescents.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.